Intersect Ent Inc
F:7IN
Intersect Ent Inc
Inventory
Intersect Ent Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Intersect Ent Inc
F:7IN
|
Inventory
$17.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Inventory
$4.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Inventory
$2.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Stryker Corp
NYSE:SYK
|
Inventory
$5.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Inventory
$6.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Inventory
$1.8B
|
CAGR 3-Years
27%
|
CAGR 5-Years
25%
|
CAGR 10-Years
27%
|
|
Intersect Ent Inc
Glance View
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company is headquartered in Menlo Park, California and currently employs 433 full-time employees. The company went IPO on 2014-07-24. The firm's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company also offers ENT products, such as VenSure and CUBE.
See Also
What is Intersect Ent Inc's Inventory?
Inventory
17.7m
USD
Based on the financial report for Mar 31, 2022, Intersect Ent Inc's Inventory amounts to 17.7m USD.
What is Intersect Ent Inc's Inventory growth rate?
Inventory CAGR 5Y
20%
Over the last year, the Inventory growth was 34%. The average annual Inventory growth rates for Intersect Ent Inc have been 8% over the past three years , 20% over the past five years .
